| 000 | 01851 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516045203.0 | ||
| 264 | 0 | _c20120222 | |
| 008 | 201202s 0 0 eng d | ||
| 022 | _a1750-7448 | ||
| 024 | 7 |
_a10.2217/imt.11.71 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGoyne, Hannah | |
| 245 | 0 | 0 |
_aCombinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer. _h[electronic resource] |
| 260 |
_bImmunotherapy _cJul 2011 |
||
| 300 |
_a805-7 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdjuvants, Immunologic |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _ximmunology |
| 650 | 0 | 4 |
_aB7-H1 Antigen _ximmunology |
| 650 | 0 | 4 |
_aCancer Vaccines _xtherapeutic use |
| 650 | 0 | 4 |
_aClonal Anergy _ximmunology |
| 650 | 0 | 4 |
_aCyclophosphamide _ximmunology |
| 650 | 0 | 4 |
_aDendritic Cells _ximmunology |
| 650 | 0 | 4 |
_aDiphosphonates _xpharmacology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xpharmacology |
| 650 | 0 | 4 |
_aImmunosuppression Therapy _xadverse effects |
| 650 | 0 | 4 |
_aImmunotherapy, Active _xmethods |
| 650 | 0 | 4 |
_aIndoleamine-Pyrrole 2,3,-Dioxygenase _ximmunology |
| 650 | 0 | 4 |
_aMacrophages _ximmunology |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aPamidronate |
| 650 | 0 | 4 |
_aT-Lymphocytes, Regulatory _ximmunology |
| 650 | 0 | 4 |
_aTh17 Cells _ximmunology |
| 650 | 0 | 4 |
_aV-Set Domain-Containing T-Cell Activation Inhibitor 1 _ximmunology |
| 650 | 0 | 4 | _aZoledronic Acid |
| 700 | 1 | _aStone, Pamela J B | |
| 700 | 1 | _aCannon, Martin J | |
| 773 | 0 |
_tImmunotherapy _gvol. 3 _gno. 7 _gp. 805-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/imt.11.71 _zAvailable from publisher's website |
| 999 |
_c21002686 _d21002686 |
||